Laverock Therapeutics

David Venables, Ph.D., CEO 

Oct. 12 | 11:00am | Rentschler ATMP Ballroom  

Stevenage, Herefordshire, UK 


Laverock Therapeutics is developing the next generation of programmable allogeneic cell therapies though our novel miRNA platform (GEiGS). Gene Editing induced Gene Silencing (GEiGS) utilizes the cells’ own endogenous miRNA expression profiles and redirects them to knock down target genes of choice, generating silencing in a stable, consistent, tunable and programmable manner in response to the stage of cell development, activation, or its’ in vivo disease related environment. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions